Agomelatine – (138112-76-2)

Agomelatine is an atypical antidepressant used primarily to treat major depressive disorder and generalized anxiety disorder. It functions as a melatonin receptor agonist and serotonin 5-HT2C receptor antagonist, which helps regulate circadian rhythms and improve mood.

Agomelatine is noted for its efficacy in treating severe depression and its relatively favorable side effect profile, with fewer sexual side effects and discontinuation symptoms compared to other antidepressants.

Common side effects include headaches, nausea, and dizziness, while liver function monitoring is recommended due to potential hepatotoxicity. Agomelatine was developed by Servier Laboratories and received approval in 2009.

The above informationis displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/Agomelatine
https://pubchem.ncbi.nlm.nih.gov/compound/82148
https://www.medchemexpress.com/Agomelatine.html
https://www.medkoo.com/products/7034
https://www.youngminds.org.uk/young-person/medications/agomelatine/#:~:text=guide
https://pmc.ncbi.nlm.nih.gov/articles/PMC3244295/